Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Feature|Podcasts|March 11, 2025
The Misinformation Maze: Navigating Public Health in the Digital Age
Author(s)Miranda Schmalfuhs
Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Advertisement
In this episode of the Pharmaceutical Executive podcast, Jennifer Butler, chief commercial officer of Pleio, discusses:
- The threat of misinformation to public health and how emotional appeal plays a part.
- Where patients are turning for trustworthy health information.
- Strategies that can be used to verify information.
- Pharma's role in helping to ensure patients have access to health insights they can trust.
- Why the industry is turning to peer-to-patient platforms, trusted patient communities, and pharmacies to educate patients.
- What kind of role regulatory agencies should play in the battle against misinformation.
- and more!
Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peet-to-patient strategies to educate patients, and more.
Advertisement
Related to this article
AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human.
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come first.
Gilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug demand and how compounding pharmacies help fill the resulting gaps.
Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona Therapeutics’ obesity RNAi candidate while Pfizer partners with Enodia Therapeutics on Sec61 inhibitors, and PaxSafe’s Mark Talens makes the case for acting on imperfect supply chain data.
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Advertisement
Advertisement
Trending on PharmExec
1
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
2
FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease
3
EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe
4
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
5